1998
December
Dr. Avinoam Dukler and his close friend Dr. Nir Dotan realize that there is little emphasis being placed on glycans, sugar molecules, despite all effort in both genetics, researching, mapping the human genome, proteomics and the study of proteins. This frustration is the inspiration to start Glycominds.
1999
February
Avinoam Dukler and Nir Dotan file a pivotal patent on developing a complex-carbohydrate library as a glycan array for the identification of novel biomarkers.
May
The LinearCode, a new syntax to describe complex glycans in a linear fashion is written by Avinoam Dukler.
August
GlycoChip® array technology is developed. This required developing breakthrough technology to immobilize glycans.
2000
January
The company completes its series A funding, raising $1.3 million, from family and friends of the founders.
August
20,000 scientific publications on glycans and human diseases are downloaded into the most comprehensive glycan database ever assembled.
December
The company identifies a proprietary set of 150 glycans relevant to autoimmunity and cancer.
2001
March
The company completes its series B round of $7.1 million with lead investors MMT and BRM Funds.
October
Glycominds and Schott Glass collaborate to develop a HTS glycan array.
2002
January
Glycominds develops a systematic approach for anti-glycan antibodies screening and completes the first proof of concept studies to discover biomarkers for diseases. This methodology is the basis for all future glycan biomarkers discovery at Glycominds.
June
The Company moves to Lod, Israel.
August
The Multiple Sclerosis GAGA4 biomarker is discovered
2003
January
Rheumatoid Arthritis and vulnerable plaque biomarkers are discovered.
September
The Crohn's disease ALCA/ACCA/AMCA biomarkers are discovered.
2004
May
The future IBDX® biomarkers are presented at DDW 2004
The MS GAGA4 biomarker is presented at ENS 2004
August
Glycominds’ Anti-glycan antibodies technology is adopted to run on industry standard Enzyme Immuno Assay Platform.
December
Glycominds adds a panel of alpha-glucose based biomarkers to supplement the MS GAGA4 marker. This panel becomes the gMS® biomarker set.
2005
May
IBDX® kits obtain the CE Mark.
October
The first validation study showing that the MS GAGA4 biomarker can be used to identify patients that will develop MS is presented by Dr. Mark Freedman at ECTRIMS 2005 conference.
December
Glycominds first glycan array patent is granted in the USA.
2006
February
Glycominds second glycan array patent is granted in the USA.
April
A novel biomarker specific for primary Anti-Phospolipid Syndrome (APS) with potential predictive value for pregnancy loss is discovered.
May
Mark Freedman presents additional validation data for the gMS® panel of biomarkers at ACTRIMS 2006
2007
Bayer Schering Pharma (BSP) agrees in principle to study the gMS® panel in its ongoing BEtaferon® in NEWLY Emerging multiple sclerosis For Initial Treatment (BENEFIT) Study.
2008
January
IBDX® lab services is launched in Israel.
February
In collaboration with ULM University and the Univeristy of Utah, successful clinical validation studies of gMS® Diagnostic Test are completed.
2009
February
The IBDX® Crohn's Prognosis Test is launched in the US by Laboratory Corporation of America - LabCorp®.
May
The US patent for the breakthrough Anti-glycan GAGA4 glycan antigen for MS Diagnosis is issued.
March
gMS®Dx testing is launched in Europe with our partner lab, Laboratoires Réunis.
August
The IBDX® Crohn's Prognosis Test is launched in the US by ARUP laboratories.
September
The GAGA4 pivotal study showing GAGA4 differential diagnosis capabilities in clinically isolated syndrome (CIS) is published.
The US patent for the panel of Anti alpha glucose glucan anti-glycans for MS differential Diagnosis is issued
The US patent for diagnosing Crohn's disease based on levels of anti-glycan antibodies, ACCA, AMCA, ALCA and gASCA is issued.
Results from the pivotal study BENEFIT presented in the ECTRIMS 2009 conference showing the significant impact of the alpha-glucose panel in predicting CIS patients at risk for confirmed EDSS progression within 5 years despite being on INFB-1b treatment.
October
The US patent for prognosing severe Crohn's disease based on levels of anti-glycan antibodies, ACCA, AMCA, ALCA and gASCA is issued.
2010
April
We launched in the US at the AAN in Toronto our 2 new tests:gMS®Dx gMS®EDSS, which will be available in September.
May
ACTRIMS, San Antonio: Presentations showed the ability of gMS®EDSS to detect RRMS patients with faster EDSS progression and the ability of gMS®Dx to differentiate RRMS patients from other inflammatory demyelinating disease patients.
DDW, New Orleans: Independent investigators presented and confirmed once again that IBDX and IBDXplus are highly valuable tools for the diagnosis and prognosis of IBD patients
August
Glycominds Inc., Clinical laboratory has been CLIA certified
|
